CRISPR Therapeutics (CRSP) Expected to Announce Earnings on Wednesday

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($1.26) per share for the quarter.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. CRISPR Therapeutics's quarterly revenue was up 71.6% on a year-over-year basis. During the same period last year, the business posted ($1.43) earnings per share. On average, analysts expect CRISPR Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock traded down $0.52 during trading on Friday, hitting $35.62. 1,737,782 shares of the company were exchanged, compared to its average volume of 1,669,274. The firm has a market capitalization of $3.08 billion, a P/E ratio of -8.15 and a beta of 1.88. The firm's fifty day moving average price is $38.15 and its 200 day moving average price is $42.77. CRISPR Therapeutics has a 1-year low of $30.04 and a 1-year high of $67.88.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Cantor Fitzgerald reiterated a "neutral" rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. Stifel Nicolaus reduced their target price on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating on the stock in a report on Thursday, February 13th. Citigroup dropped their price target on CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating on the stock in a research report on Tuesday, February 18th. TD Cowen raised CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 target price for the company in a research note on Wednesday, February 12th. Finally, Evercore ISI raised shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and lifted their price target for the company from $60.00 to $99.00 in a research note on Friday, February 14th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, CRISPR Therapeutics presently has a consensus rating of "Hold" and an average target price of $71.58.

Insider Activity

In other CRISPR Therapeutics news, COO Julianne Bruno sold 1,198 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $50,819.16. Following the completion of the sale, the chief operating officer now owns 8,263 shares in the company, valued at $350,516.46. The trade was a 12.66 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Samarth Kulkarni sold 18,360 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares of the company's stock, valued at approximately $9,473,037.60. This trade represents a 9.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 32,381 shares of company stock valued at $1,608,243 over the last ninety days. 4.30% of the stock is currently owned by company insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.